<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00108459</url>
  </required_header>
  <id_info>
    <org_study_id>ENDA-002-03F</org_study_id>
    <nct_id>NCT00108459</nct_id>
  </id_info>
  <brief_title>Low Carbohydrate Diet Compared to Calorie and Fat Restricted Diet in Patients With Obesity and Type II Diabetes</brief_title>
  <official_title>Safety and Efficacy of Low Carbohydrate Diet in Obesity and Type 2 DM: RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <brief_summary>
    <textblock>
      This study is designed to address the hypothesis that in obese patients with type 2 diabetes&#xD;
      mellitus (DM), a low carbohydrate diet not specifically restricted in calories compared to&#xD;
      low fat, caloric restricted diet over 24 months will cause 5% greater reduction in body&#xD;
      weight in patients with obesity and type 2 DM, be safe, and will not have any detrimental&#xD;
      effects on serum lipid concentrations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      This study is designed to address the hypothesis that in obese patients with type 2 DM, a low&#xD;
      carbohydrate diet not specifically restricted in calories compared to low fat, caloric&#xD;
      restricted diet over a 24 months period will:&#xD;
&#xD;
        -  Primary:&#xD;
&#xD;
             1. Cause 5% greater reduction in body weight in patients with obesity and type 2 DM;&#xD;
&#xD;
             2. Be safe and will not have any detrimental effects on serum lipid concentrations&#xD;
&#xD;
        -  Secondary:&#xD;
&#xD;
             1. Lead to a greater reduction in HbA1c and fasting serum glucose and insulin&#xD;
                concentration;&#xD;
&#xD;
             2. Lead to reduction in body fat content;&#xD;
&#xD;
             3. Cause greater reduction in serum triglyceride concentration;&#xD;
&#xD;
             4. Cause no significant changes in proteinuria, serum low-density lipoprotein (LDL),&#xD;
                high-density lipoprotein (HDL), creatinine and uric acid concentrations&#xD;
&#xD;
        -  Exploratory:&#xD;
&#xD;
      Cause favorable changes in adipocytokines (serum leptin, resistin, TNF-α, TNF α- receptors,&#xD;
      free fatty acids) and high sensitive C-reactive protein&#xD;
&#xD;
      Research Design:&#xD;
&#xD;
      This will be a single site (Philadelphia VA Medical Center); two arm, parallel, randomized,&#xD;
      clinical trial. Obese, male, type 2 diabetic subjects (body mass index [BMI] &gt;30 kg/m2) will&#xD;
      be randomized in a 1:1 fashion to dietary instructions for low carbohydrate or low fat diet.&#xD;
      Women will be randomized separately (blocks of 4) to ensure equal representation in both&#xD;
      dietary groups. Recruitment will be done in 3 phases (for logistical reasons). Subjects will&#xD;
      be randomized to one of the two dietary groups. One group will be instructed on a&#xD;
      carbohydrate-restricted diet, and the other on a calorie and fat restricted diet as&#xD;
      recommended by the National Heart, Lung and Blood Institute (NHLBI). All patients will have&#xD;
      blood, urine, and body composition analyses measured at baseline and then at 26, 52, and 104&#xD;
      weeks. Dietary instructions will be given to subjects in groups of 13, and will be provided&#xD;
      every week for the first 4 weeks and then every 4 weeks for a total of 30 visits.&#xD;
&#xD;
      Methodology: The setting is the outpatient clinics of the Philadelphia Veterans Affairs&#xD;
      Medical Center. Inclusion criteria include: Male or female subjects &gt; 18 years of age;&#xD;
      Clinical diagnosis of type 2 diabetes mellitus; Body mass index of &gt; 30 kg/m2 . Approximately&#xD;
      156 male and female veterans from the Philadelphia Veterans Affairs Medical Center will be&#xD;
      enrolled in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date>December 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Hyperlipidemia</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low Carbohydrate Diet</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects &gt; 18 years of age&#xD;
&#xD;
          -  Clinical diagnosis of type 2 diabetes mellitus or on insulin or oral hypoglycemic&#xD;
             agents&#xD;
&#xD;
          -  Body mass index of &gt; 30 kg/m2&#xD;
&#xD;
          -  The subject must we willing and able to monitor their blood glucose with a glucometer&#xD;
             at least 2 times per week.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nayyar Iqbal</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>April 15, 2005</study_first_submitted>
  <study_first_submitted_qc>April 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2005</study_first_posted>
  <last_update_submitted>January 20, 2009</last_update_submitted>
  <last_update_submitted_qc>January 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2009</last_update_posted>
  <keyword>Obesity</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

